Lazard Asset Management
CATX icon

Lazard Asset Management’s Perspective Therapeutics CATX Stock Holding History

Lazard Asset Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-523
Closed -$5K – 2283
2024
Q2 		$5K Buy
+523
New +$7.56K ﹤0.01% 2062

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lazard Asset Management's CATX Position: Q3 2024 in Review

Lazard Asset Management sold out of Perspective Therapeutics (CATX) in Q3 2024, closing a stake of 523 shares — an estimated $5K sold.

Lazard Asset Management first reported a position in CATX in Q2 2024 and held it in 1 quarter. The position peaked at $5K in Q2 2024. 127 funds tracked by Wall St. Rank hold CATX as of Q3 2024.

  • Lazard Asset Management reported no remaining Perspective Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Lazard Asset Management sold 523 Perspective Therapeutics shares in Q3 2024, an estimated $5K.
  • Lazard Asset Management first reported a position in Perspective Therapeutics in Q2 2024 and held it in 1 quarter.
  • Lazard Asset Management's Perspective Therapeutics position peaked at $5K in Q2 2024.
  • 127 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2024.

Based on Lazard Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.